Pulmonary Pharmacology · Module 6 of 7

Cystic Fibrosis CFTR Modulator Pharmacology

Mutation class taxonomy · Correctors and potentiators · Triple combination therapy · Drug interactions · Non-modulator management

CFTR is a cyclic AMP-activated Cl⁻/HCO₃⁻ channel on airway epithelium; PKA phosphorylation of the regulatory domain activates it; NBDs bind and hydrolyze ATP to gate it open. Normal CFTR drives Cl⁻/water secretion into the airway lumen, maintaining the periciliary liquid layer for mucociliary clearance. CF mutations produce viscous, dehydrated secretions → impaired ciliary clearance → chronic bacterial colonization, bronchiectasis, and obstructive lung disease (>80% of CF mortality). Modulators rescue the defective protein at the folding, trafficking, or gating level — they do not repair the underlying gene mutation.
Six mutation classes predict modulator eligibility: Class I (premature stop codon → no protein; no approved modulator). Class II (misfolding → ER degradation before cell surface; F508del most prevalent, ~85–90% of CF patients on ≥1 allele → target of correctors). Class III (protein reaches membrane but gates abnormally; G551D prototype → target of potentiators). Classes IV–VI (reduced conductance / reduced protein quantity / surface instability). Correctors (elexacaftor, tezacaftor, lumacaftor) assist folding/trafficking to get protein to the surface; potentiators (ivacaftor) increase gate-opening probability for protein already there. F508del has BOTH a Class II folding defect AND a Class III gating defect — requires both corrector and potentiator.
Ivacaftor (Kalydeco): first approved CFTR modulator; binds CFTR at the cell surface → increases probability of gate opening in response to PKA phosphorylation; active only on protein already at the apical membrane → effective only for Class III gating mutations. Approved for G551D and >95 other gating/residual function mutations. STRIVE trial: +10 percentage points FEV1% predicted, −55% exacerbations, dramatic sweat chloride reduction, sustained weight gain — unprecedented at the time. No meaningful efficacy as monotherapy in F508del homozygous patients (too little protein reaches the surface without a corrector).
Dual therapy — lumacaftor/ivacaftor (Orkambi): lumacaftor stabilizes F508del during synthesis → more protein escapes ER quality control → reaches surface; ivacaftor potentiates gating. F508del homozygous age ≥6. TRAFFIC/TRANSPORT: +2–4% FEV1, −39% exacerbations — modest. Critical PK problem: lumacaftor is a potent CYP3A4 inducer → dramatically reduces ivacaftor plasma concentrations → partial self-sabotage; also causes respiratory AEs (chest tightness/dyspnea) at initiation. Tezacaftor/ivacaftor (Symdeko): second-generation corrector; NOT a CYP3A4 inducer; cleaner PK profile; slightly better tolerated; F508del homozygous and some residual function mutations age ≥6. Both superseded by triple combination for eligible patients.
Triple combination — elexacaftor/tezacaftor/ivacaftor (Trikafta): elexacaftor binds membrane-spanning domain 1 (different site from tezacaftor) + tezacaftor binds nucleotide-binding domain 1 → two correctors at distinct sites → additive/cooperative F508del protein stabilization → far greater protein rescue than single-corrector regimens → ivacaftor potentiates gating of the rescued protein. Eligible: ≥1 F508del allele, age ≥2 (~90% of CF patients). Pivotal trials: +14% FEV1, −63% exacerbations, near-normalization of sweat chloride. CYP3A4 substrate: avoid strong inducers (rifampin, certain anticonvulsants — reduce levels); reduce dose with strong inhibitors (azole antifungals, certain antiretrovirals — increase exposure). Monitor transaminases: every 3 months year 1, annually thereafter; hold if ALT/AST >3× ULN. Modulators do not reverse existing bronchiectasis or eliminate established Pseudomonas/Staph colonization.

ALT = alanine aminotransferase · AST = aspartate aminotransferase · ATP = adenosine triphosphate · CF = cystic fibrosis · CFTR = cystic fibrosis transmembrane conductance regulator · ER = endoplasmic reticulum · ETI = elexacaftor/tezacaftor/ivacaftor · FEV1 = forced expiratory volume in 1 second · MSD = membrane-spanning domain · NBD = nucleotide-binding domain · PKA = protein kinase A · ULN = upper limit of normal

CFTR Mutation Classes and Drug Targets

Class	Defect	Protein Problem	Modulator Type	Agents
Class I	Premature stop codon	No full-length protein produced; most severe	None approved	Investigational only
Class II	Misfolding + trafficking failure (F508del)	ER quality control degrades protein before it reaches the cell surface	Correctors	Elexacaftor, tezacaftor, lumacaftor
Class III	Gating defect (G551D)	Protein reaches cell surface but channel gate won't open normally	Potentiator	Ivacaftor
Class IV–VI	Reduced conductance / quantity / stability	Reduced ion flow, reduced protein amount, or rapid surface turnover	Ivacaftor (some); correctors where F508del present	ETI for F508del allele; ivacaftor for residual function mutations

Corrector vs. Potentiator Mechanism

Correctors — Class II Target

Fix Folding and Trafficking

F508del protein misfolds in the ER → recognized by quality control → degraded before reaching the cell surface
Correctors bind CFTR and stabilize its folding during synthesis → allow more protein to escape ER degradation
Result: more CFTR protein successfully traffics to the apical cell membrane
Elexacaftor binds MSD1; tezacaftor binds NBD1 — distinct sites, additive effect
Lumacaftor: first-generation, different binding; potent CYP3A4 inducer (self-sabotage with ivacaftor)

Potentiator — Class III Target

Fix Channel Gating at the Surface

Gating mutation protein (e.g., G551D) reaches the cell surface normally but cannot open the channel gate in response to PKA phosphorylation
Ivacaftor binds CFTR at the cell surface → increases probability of gate opening → restores Cl⁻ flux
Acts ONLY on protein already at the cell surface — cannot rescue misfolded protein
No benefit in F508del monotherapy (too little protein reaches the surface without a corrector)
F508del has BOTH a folding defect AND a gating defect → requires corrector + potentiator

Approved Modulator Regimens — Evolution of Therapy

Potentiator Monotherapy

Ivacaftor (Kalydeco)

Class III gating mutations: G551D + >95 other gating/residual function mutations
STRIVE trial: +10% FEV1, −55% exacerbations, dramatic sweat Cl⁻ reduction, weight gain
First proof that CFTR-targeted therapy could transform disease outcomes
No benefit in F508del monotherapy
CYP3A4 substrate; dose reduce with strong CYP3A4 inhibitors

Dual Therapy — F508del Homozygous

Lumacaftor / Ivacaftor (Orkambi)

F508del homozygous, age ≥6
TRAFFIC/TRANSPORT: +2–4% FEV1, −39% exacerbations — modest improvement
Lumacaftor is a potent CYP3A4 inducer → dramatically reduces ivacaftor plasma levels → partial self-sabotage requiring higher ivacaftor doses
Respiratory AEs at initiation (chest tightness, dyspnea) — particularly in severe disease
Superseded by triple combination for eligible patients

Dual Therapy — Improved PK

Tezacaftor / Ivacaftor (Symdeko)

F508del homozygous + certain residual function mutations; age ≥6
Second-generation corrector — different mechanism from lumacaftor
NOT a CYP3A4 inducer — cleaner pharmacokinetic profile than Orkambi
Lower rates of respiratory AEs than lumacaftor/ivacaftor
Modest efficacy — similarly superseded by triple combination for eligible patients

Triple Combination: Elexacaftor / Tezacaftor / Ivacaftor (Trikafta)

Mechanism — Dual Corrector + Potentiator

Three-Drug Rescue of F508del

Elexacaftor: next-generation corrector; binds MSD1 — distinct from tezacaftor's NBD1 site
Tezacaftor: corrector at NBD1 — contributes additional protein stabilization
Two correctors at DISTINCT sites → additive, cooperative F508del protein stabilization → far greater rescue than single-corrector regimens
Ivacaftor: potentiates gating of the rescued protein at the cell surface
Net result: sufficient CFTR protein rescue to normalize or near-normalize channel function

Efficacy and Eligibility

Transformative Clinical Results

Eligible: ≥1 F508del allele, age ≥2 — covers ~90% of CF patients
+14% FEV1 at 24 weeks (vs +2–4% with dual therapy)
−63% pulmonary exacerbations
Near-normalization of sweat chloride (<30 mmol/L in many patients)
Effective in F508del heterozygotes (one F508del + one minimal function allele) — for whom no prior modulator was available

Drug Interactions, Monitoring, and Residual Management

ETI — CYP3A4 Interactions

Dose Adjustments Required

ETI is a CYP3A4 substrate — levels altered by CYP3A4 modulators
Strong CYP3A4 inhibitors (azole antifungals, some antiretrovirals): substantially increase elexacaftor and ivacaftor exposure → dose reduce ETI
Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): reduce drug levels → avoid combination
Moderate inhibitors: dose adjustment based on specific agent

Monitoring

Sweat Chloride and LFTs

Sweat chloride: primary pharmacodynamic biomarker of CFTR function; normal <30 mmol/L; untreated CF typically >60 mmol/L
Effective ETI: near-normalizes sweat chloride — confirms CFTR rescue at biochemical level
LFTs: every 3 months for year 1, then annually on ETI
ALT or AST >3× ULN → interrupt treatment; reassess before restarting

Non-Modulator Therapies

Continue Alongside Modulators

Modulators do NOT reverse established bronchiectasis or clear existing Pseudomonas/Staph colonization
Dornase alfa (DNase): cleaves neutrophil extracellular DNA in airway secretions → reduces viscosity; continue on modulators
Hypertonic saline 7%: osmotic rehydration of periciliary liquid layer → improves mucociliary transport
Inhaled antibiotics (tobramycin, aztreonam): suppress chronic Pseudomonas colonization
Airway clearance: high-frequency oscillation, PEP devices — daily cornerstone

Who Gets Which Modulator — Selection Framework

≥1 F508del allele, age ≥2: elexacaftor/tezacaftor/ivacaftor (Trikafta) — first choice for all eligible patients. This covers approximately 90% of the CF population and should be used in preference to dual-agent combinations when available.

Class III gating mutation, no F508del: ivacaftor (Kalydeco) monotherapy. Approved for G551D and >95 other gating/residual function mutations.

F508del homozygous where triple combination unavailable: tezacaftor/ivacaftor (Symdeko) preferred over lumacaftor/ivacaftor (Orkambi) due to cleaner pharmacokinetic profile. Both are inferior to ETI.

Class I or Class II without F508del: no approved modulator in most cases; investigational approaches (e.g., read-through agents for stop codons) are in development.

Suggested References

Author / Source	Title	Publication
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed.	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
Rowe SM, Miller S, Sorscher EJ	Cystic fibrosis	N Engl J Med. 2005;352(19):1992–2001
Welsh MJ, Smith AE	Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis	Cell. 1993;73(7):1251–1254
Boyle MP, De Boeck K	A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect	Lancet Respir Med. 2013;1(2):158–163
Ramsey BW, Davies J, McElvaney NG, et al	A CFTR potentiator in patients with cystic fibrosis and the G551D mutation	N Engl J Med. 2011;365(18):1663–1672
Wainwright CE, Elborn JS, Ramsey BW, et al	Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR	N Engl J Med. 2015;373(3):220–231
Taylor-Cousar JL, Munck A, McKone EF, et al	Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del	N Engl J Med. 2017;377(21):2013–2023
Heijerman HGM, McKone EF, Downey DG, et al	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation	Lancet. 2019;394(10212):1940–1948
Middleton PG, Mall MA, Drevinek P, et al	Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele	N Engl J Med. 2019;381(19):1809–1819
Van Goor F, Hadida S, Grootenhuis PDJ, et al	Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770	Proc Natl Acad Sci USA. 2009;106(44):18825–18830
Lommatzsch ST, Taylor-Cousar JL	The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis	Ther Adv Respir Dis. 2019;13:1753466619844424